StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Climb Bio (CLYM)

Mon, 12 Oct 2026 06:54:35 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $30.00 price target on Climb Bio (NASDAQ: CLYM).

The analyst commented: "We draw investors' attention to the fact that Climb Bio is slated to present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, CO from October 21-25, 2026. On October 22, 2026, a poster entitled "CLYM116, a Novel "Sweeper" Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Development for IgAN: Phase 1 Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Results in

Raymond James Reiterates Strong Buy Rating on Climb Bio (CLYM)

Mon, 05 Oct 2026 05:17:24 -0400

Raymond James analyst Christopher Raymond reiterated a Strong Buy rating and $34.00 price target on Climb Bio (NASDAQ: CLYM).

The analyst comments "Remain Strong Buy rated on CLYM shares following the release of the abstract for initial P2 budoprutug (budo) data in primary membranous nephropathy (pMN) to be presented at ASN Kidney Week on October 24. Recall CLYM has previously guided that this data release would likely only encompass safety and short-term biomarker data for the low dose (200 mg) cohort. As of the abstract’s data cut-off, 11 patients have been enrolled in this cohort, with 5 patients having been administered

Climb Bio to present kidney disease data at ASN 2026 conference

Fri, 02 Oct 2026 09:30:18 -0400

Climb Bio, Inc. (Nasdaq: CLYM) announced it will present clinical data for its CLYM116 and budoprutug programs at the American Society of Nephrology Kidney Week 2026, scheduled for October 21–25 in Denver, Colorado.

The company will deliver four presentations covering three immune-mediated kidney diseases. Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy has been selected for an oral presentation on October 24.

Two poster presentations on CLYM116, an anti-APRIL monoclonal antibody in development for IgA nephropathy, will share Phase 1 safety, tolerability, pharmacokinetics, and pharmacodynamics results from healthy volunteer studies. These posters are scheduled for

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Fri, 02 Oct 2026 09:30:00 -0400

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, Colorado

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Fri, 02 Oct 2026 09:30:00 -0400

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

1. Xencor Inc. (XNCR)

Raymond James added Xencor to its top picks list, replacing Relay Therapeutics. The firm anticipates significant interest in Xencor's dataset at ESMO at the end of October. Raymond James sees near-term upside to shares on a positive readout and clear path to pivotal development for

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Raymond James Updates Healthcare Top Picks for October

Thu, 01 Oct 2026 16:00:03 -0400

1. Xencor Inc. (XNCR)

Form 4 Climb Bio, Inc. For: Sep 28 Filed by: RA Capital Nexus Fund, L.P.

Wed, 30 Sep 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260930/27129272.html

Raymond James Adjusts Analyst Current Favorites List

Wed, 23 Sep 2026 06:31:22 -0400

Raymond James Adjusts Analyst Current Favorites List

ADDS: Climb Bio (NASDAQ: CLYM)
REMOVES: Tyra Biosciences (NASDAQ: TYRA)

The analyst comments "Climb Bio, Inc. (CLYM) is our Analyst Current Favorite given what we think is an increasingly derisked setup for both of CLYM’s lead assets – CLYM116 and budoprutug. For anti-APRIL antibody CLYM116, recent Phase 1 data demonstrated the ability to achieve strong levels of IgA reduction with a plausible every 3-month dosing scheme, which could lead to a best-in-class profile in this expanding multi-billion dollar market. CLYM anticipates sharing initial data from a Phase 2 study next year, which should solidify CLYM116’s efficacy

Raymond James Adjusts Analyst Current Favorites List

Wed, 23 Sep 2026 06:31:22 -0400

Raymond James Adjusts Analyst Current Favorites List

ADDS: Climb Bio (NASDAQ: CLYM)
REMOVES: Tyra Biosciences (NASDAQ: TYRA)

Form 4 Climb Bio, Inc. For: Sep 15 Filed by: Thomas Stephen Basil

Thu, 17 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260917/27076023.html

Form 144 Climb Bio, Inc. Filed by: Thomas Stephen Basil

Tue, 15 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260915/27065206.html

Climb Bio (CLYM) PT Raised to $30 at H.C. Wainwright

Tue, 08 Sep 2026 07:38:03 -0400

(Updated - September 8, 2026 7:38 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $24.00) while maintaining a Buy rating.

The analyst commented: "As presented last week, CLYM116 showed dose-proportional exposure, linear clearance above 1 µg/mL, and no observed target-mediated drug disposition at clinically relevant concentrations. Based on the 320mg multiple ascending dose (MAD) cohort, Climb projects an approximately 29-day half-life. A single 320mg dose suppressed free APRIL by >90% through Week 10 and more than 75% at Week 12, with ~60% IgA, >70% Gd-IgA1, and ~75% IgM reductions maintained through

Climb Bio (CLYM) PT Raised to $30 at H.C. Wainwright

Tue, 08 Sep 2026 07:38:03 -0400

(Updated - September 8, 2026 7:38 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $24.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $25 at Oppenheimer

Tue, 08 Sep 2026 07:14:10 -0400

Oppenheimer analyst Leland Gershell raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $18.00) while maintaining a Outperform rating.

The analyst comments "The recent CLYM116 reveal illustrates a best-in-class clinical profile for IgAN as echoed by our KOL discussion. Clear Q12W dosing support with IgA suppression to typical anti-APRIL depths put CLYM116 on solid competitive footing to JBIO's JADE101 among other class members, and safety featured no surprises. An initial look from partner Mabworks' Phase 2 in IgAN patients is on track for 1H, and Phase 3 is slated to begin next year. We believe CLYM116 is shaping

Climb Bio (CLYM) PT Raised to $25 at Oppenheimer

Tue, 08 Sep 2026 07:14:10 -0400

Oppenheimer analyst Leland Gershell raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $18.00) while maintaining a Outperform rating.

Climb Bio (CLYM) PT Raised to $30 at B.Riley

Fri, 04 Sep 2026 08:24:56 -0400

B.Riley analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $30.00 (from $26.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $32 at BTIG

Thu, 03 Sep 2026 13:21:00 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $32.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "CLYM116's Phase 1 results were within our positive previewed scenario, with CLYM116 showing the potential for Q12W dosing and ~55% IgA reduction at 12wk seen with the 320mg dose (most comparable to VOYXACT commercial dose and JADE101 350mg dose). CLYM116 showed rapid and sustained free APRIL (fAPRIL) suppression, with >90% suppression through 10wk and >75% suppression maintained through 12wk. No ADA data were shared, although mgmt. noted there has been nothing seen from the existing data

Climb Bio (CLYM) PT Raised to $32 at BTIG

Thu, 03 Sep 2026 13:21:00 -0400

BTIG analyst Julian Harrison raised the price target on Climb Bio (NASDAQ: CLYM) to $32.00 (from $20.00) while maintaining a Buy rating.

Climb Bio (CLYM) PT Raised to $25 at Baird

Thu, 03 Sep 2026 12:15:37 -0400

Baird analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $21.00) while maintaining a Outperform rating.

The analyst comments "Raising target on differentiated PK/PD data. The Ph1 data for CLYM116 are encouraging, with near-complete APRIL suppression and impressive reductions in IgA and Gd-IgA1 in healthy volunteers. We think this suggests a profile that is likely similar to earlier-gen anti-APRILs but with a substantially longer half life. With initial Ph2 data 1H27 and a planned 2027 Ph3 initiation, we see a nice pacing of data for the program. We're raising our probability of success to 50%

Climb Bio (CLYM) PT Raised to $25 at Baird

Thu, 03 Sep 2026 12:15:37 -0400

Baird analyst Mayank Mamtani raised the price target on Climb Bio (NASDAQ: CLYM) to $25.00 (from $21.00) while maintaining a Outperform rating.

Climb Bio reports Phase 1 data for CLYM116 in IgA nephropathy

Thu, 03 Sep 2026 07:00:37 -0400

Climb Bio, Inc. (Nasdaq: CLYM) released initial Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy (IgAN), according to a company statement.

The Phase 1 trial was a randomized, double-blind, placebo-controlled, single- and multiple-ascending-dose study enrolling 46 healthy volunteers. It evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous CLYM116.

Key findings include a projected half-life of approximately 29 days based on the 320 mg multiple-ascending-dose cohort. A single 320 mg dose produced greater than 90% free APRIL suppression and approximately 60–75% suppression of IgA, Gd-IgA1, and IgM, with suppression maintained through 12 weeks. The company reported

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Thu, 03 Sep 2026 07:00:00 -0400

~29-day half-life

Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks

CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia

Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027

Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET

WELLESLEY HILLS, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Thu, 03 Sep 2026 07:00:00 -0400

~29-day half-life

Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks

CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia

Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027

Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET

WELLESLEY HILLS, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics